Updated results of the global phase III ALEX trial comparing alectinib with crizotinib as first-line treatment against ALK-positive non-small cell
Continue reading »Home ยป
Alectinib provides longer symptom improvement than crizotinib in ALK-positive lung cancer
Alectinib provides longer symptom improvement than crizotinib in ALK-positive non-small-cell lung cancer (NSCLC), according to results from the ALEX trial
Continue reading »